
The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.
Across the pharmaceutical industry, coverage does not inherently mean access. As a result, the industry must overcome "policy fatigue" by rethinking access strategies, pricing models, and organizational integration to bridge the critical gap between product coverage and real-world patient access.






